insurers glp-1 coverage news Navigating Insurance for Medication: Visual Guide Some US employers to drop

Save Face, a register of accredited practitioners, said it had recorded 90 complaints about the product so far in 2023 50 in the past three months compared with just one complaint in the whole of 2022

Key distinctions in the evidence: Tesamorelin: licensed in the US, narrowly indicated, established in HIV-related lipodystrophy, with effects that reverse on stopping treatment Retatrutide: investigational, broader metabolic potential, not yet approved anywhere globally Patients and clinicians should interpret early-phase data for retatrutide with appropriate caution

Increasing vegetable intake supports ongoing cellular detoxification

Xenobiotica 39(3):197204

Give it a full 90 days

Adequate hydration, sufficient dietary fiber, and regular physical activity support normal bowel function